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Abstract
The dry powder inhaler (DPI) is a popular, effective and convenient drug delivery
device for inhalation therapy to treat asthma. However, a large quantity (approximately
54%) of inhaled aerosols deposit in the oropharyngeal region. Deposition in this
region is undesirable because it provides minimum therapeutic benefits and has
adverse localized or systemic side effects. This study reports a method of examining
electrostatic charge effects on deposition of three DPI aerosols (Spiriva™ Handihaler,
Advair Diskus™, and Pulmicort™ Turbohaler) in a cadaver-based cast of the human
oral-pharyngeal-laryngeal (OPL) regions. Experimental aerosols were generated
from the three commercially available DPIs by means of inhalation as boluses, and
then characterized with an electronic single particle aerodynamic relaxation time
analyzer with or without passing through the OPL regions. The results showed that
aerosol particles were not only of different sizes but also carried different positive,
negative and zero electrostatic charges. The deposition fraction of total particles
(charged and uncharged) in the OPL regions for the Spiriva, Advair and Pulmicort were
22%, 61% and 7%, respectively, whereas the deposition fraction of charged particles
in the Spiriva, Advair and Pulmicort generated aerosols were 62%, 67% and 28%,
respectively. The inherent net charge to mass ratio were Spiriva 0.76 ± 0.11 µC/g
(negative), Advair Diskus 0.49 ± 0.3 µC/g (negative), and Pulmicort 0.46 ± 0.02
(µC/g (negative), respectively. The study results also revealed that inherent charges of
smaller (aerodynamic diameter, da < 2.0 ∝m) particles influenced their agglomeration,
and therefore, increased their deposition due to inertial impaction and electrostatic
space charge forces. In addition, the deposition fraction of these charged particles
rapidly increased for Spiriva and Advair but marginally increased for Pulmicort with
increasing particle sizes. Electromechanical properties (both aerodynamic size and
electrostatic charge) play significant roles in the deposition of dry powder inhaler
aerosols in the human oral-pharyngeal-laryngeal regions.

ABBREVIATIONS

INTRODUCTION

DPI: Dry Powder Inhaler; OPL: Oral-Pharyngeal-Laryngeal;
ET: Extra Thoracic; COPD: Chronic Obstructive Pulmonary
Disease; ELPI: Electrical Low Pressure Impactor; ESPARTA:
Electronic Single Particle Aerodynamic Relaxation Time
Analyzer; USP: United States Pharmacopoeia; ETS: Electro-Tech
Systems; CMAD: Count Median Aerodynamic Diameter; MMAD:
Mass Median Aerodynamic Diameter; GSD: Geometric Standard
Deviation; SD: Standard Deviation; DE OPL: Deposition Efficiency
In The Oral-Pharyngeal-Laryngeal Region

The oral-pharyngeal-laryngeal (OPL) deposition is the major
determinant for lung deposition of an inhaled aerosol [1]. In
order to be delivered to the target receptors of the intrathoracic
lung, aerosolized pharmaceutical agents must first traverse and
penetrate the extra thoracic (ET) airway (i.e., passages of the
mouth and throat) [2-4]. That is, to elicit optimum therapeutic
responses, medicinal agents such as bronchodilators and steroids
employed in the management of asthma should be selectively
distributed among lung airways. To accomplish this task, it is
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imperative that the particle filtering characteristics of the ET
region be acknowledged when delivering aerosolized medicines
to the lungs [5].

The dry powder inhaler (DPI) is a popular drug delivery
device used in the treatment of respiratory diseases, such as
asthma and chronic obstructive pulmonary diseases (COPDs),
because 1) it has been shown to be effective and convenient to use,
2) it does not contain propellant and can remain with required
physiochemical properties in a wide change of environmental
conditions. As noted, the localized deposition of drug particles at
desired sites, such as inflamed tissue, and appropriate receptors
has been recognized by clinical investigators as being critical for
the effective administration of asthma drugs. Approximately 54%
of inhaled aerosols are lost in the oropharyngeal region [6-8].
These deposited drugs are swallowed, enter the gastrointestinal
tract, and cause systemic side effects [7]. Furthermore, the
low thoracic delivery efficiencies of costly drugs would be an
impediment to their use [2,8,9]. It is therefore appropriate to
study the particles’ electromechanical properties on deposition
behavior in the oral-pharyngeal-laryngeal (OPL) regions.
Several studies have found that electrostatic charge forces
influence particle deposition in the ET region along with
more commonly recognized forces like inertial impaction,
sedimentation, and diffusion [10-17]. It is an accepted practice
that most DPI formulations consist of micronized drug blended
with larger carrier particles. The electrostatic interaction between
drug and carrier is a major determinant of DPI performance like
other attributes such as particle size, flow property, formulation,
drug-carrier adhesion, respiratory flow rate, and device
geometry [18]. This study employed three different DPIs with
different formulations, devices, doses and manufacturers. As a
result, their electrostatic charge properties were different due to
the combined effects of these factors, and the effect of this charge
on deposition variation in the OPL was the aim of this study.
The DPI aerosol particles acquire charges via electron and ion
transfer during particle-particle and particle-device component
contact and separation. More importantly, respiratory airways
are conductive but do not prevent particles from charging [19].
The charge distributions (both magnitude and polarity) are
dependent on the work functions of the materials coming in
contact with each other, the friction and surface area involved
in the contact, dielectric properties of the materials, and the
ambient relative humidity. The charge magnitude is affected by
numerous factors, including drug propellant surfactants, metal
surfaces of delivery devices, drug/carrier homogeneities, and
excipient particles size distribution [19,20]. Although, it has
been standard laboratory procedure to pass an aerosol through
a charge neutralizer to attain a Boltzmann equilibrium (i.e.,
zero net charge), a DPI aerosol has only a slight possibility to
become charge neutralized before inhalation [21]. Electrostatic
properties of particles consist of: (a) mutual repulsion between
particles due to space charge forces, subsequently influencing
agglomeration and interactions with other particles; and (b)
mutual attraction between particles and neutral inner surfaces
of airways due to image charge forces [19,22]. Both forces are
dependent on the airborne particle number density [21]. In
addition, the adhesive forces among drug particles are due to the
J Drug Des Res 2(1): 1009 (2015)

electromagnetic forces that act between electrons and protons of
the individual molecules [20]. A study with 0.6 µm carnauba wax
particles showed that deposition increased from 13% to 22%
when the number of elementary charges on particles increased
from 2.7 to 7.5 µC [23]. Balachandran [24] reported that a low
particle charge (approximately 10 µC per 2 µm particle) produced
enhanced pulmonary deposition, while a higher particle charge
(approximately 300 µC per particle) favored deposition in the
upper airways.
In the literature it has been reported that particle sizes and
device geometries affect ET losses [21,25]. However, charge
acquisition due to mouth-throat turbulence and its subsequent
role on deposition has not been elucidated. The major reason of
this lack of information has been the unavailability of a suitable
measuring instrument. Drug aerosol characterization studies
have used an electrical low pressure impactor (ELPI) to analyze
aerosol particle charges [26, 27]. However, the ELPI has a
limitation because it provides only the net charge of all particles
deposited on its impactor plate rather than for each particle
in real time. To resolve this issue, this work used an electronic
single particle aerodynamic relaxation time analyzer (ESPARTA)
to perform electric charge measurements on a single particle
basis and in real time [26]. This investigation had two specific
objectives: (1) to characterize and compare the aerodynamic
sizes and electrostatic charges of aerosols generated by three
DPIs; and (2) to study the effects of these properties on aerosol
deposition in a replica cast of the human oral-pharyngeallaryngeal airways (Figure 1). Aerosol researchers usually employ
the United States Pharmacopoeia (USP) metal throat or glass
throat impinger to sample particles for characterization in an
Andersen Cascade Impactor. Studies have found that the metal
USP throat and glass throat impinger have significant deposition
differences, and the deposition in both were lower than in vivo
data [9,28]. A chief motivation for using the OPL replica cast in
this study was its intrinsic similarity to in vivo airway anatomy.

MATERIALS AND METHODS

The experimental system consisted of several components,
which are addressed below.

Figure 1 Cadaver-based cast of the human oral-pharyngeal-laryngeal
(OPL) regions.
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(i) Three delivery devices and drugs were studied. (1)
DPI Spiriva™ Handihaler, drug tiotropium bromide, 18 mcg
per capsule with lactose monohydrate as carrier (Boehringer
Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA).
(2) DPI Advair Diskus™ 500/50, single blister contained the
drug fluticasone propionate 500 mcg and salmeterol 50 mcg
inhalation powder (GlaxoSmithKline, Research Triangle Park,
North Carolina, USA). (3) DPI Pulmicort™ Turbo haler, each
metered dose contained 200 mcg budesonide inhalation powder,
but the data on excipient amount was not available. (AstraZeneca,
Wilmington, Delaware, USA). Three aerosol devices were used for
each type of DPIs. Even though all of the formulations contained
both are active pharmaceutical ingredient and an excipient,
their unequal quantities did not affect the measurement of
aerodynamic diameters and electrostatic charges because the
ESPARTA instrument characterized each bolus for a period of 5
minutes only (Figure 1).

(ii) The replica cast (Figure 1) was made of polyester
resin. It was a life-sized model and included the continuous
OPL passages of a healthy 82-year-old male subject. It was
made from a post-mortem negative cast and was prepared in
the Division of Pulmonary and Critical Care Medicine at the
University of California, Irvine, California, USA. The replica OPL
cast was placed in a controlled chamber designed to simulate
the humid environment inside a human. The relative humidity
was maintained above 95% with an automatic humidity
controller (Model 514, ETS Electro-Tech Systems, Inc., Glenside,
Pennsylvania, USA). The chamber and lab temperature were
same, and it was measured 37oC by using an Extech Heavy
Duty Hot Wire Thermo-Anemometer (Extech Instruments,
Waltham, Massachusetts, USA).
(iii) The Electronic Single Particle Aerodynamic Relaxation
Time Analyzer (ESPARTA) was used to measure aerodynamic
sizes and electrostatic charges in real time. It was designed
and developed in the Aerosol Drug Delivery Research Lab of
the University of Arkansas at Little Rock, Little Rock, Arkansas,
USA [26]. Its application in the area of aerosol medicine was
demonstrated elsewhere [29].

(iv)An aerosol sampling chamber held aerosols for
characterization (Figure 2). It had a volume of 28.3 liters and
four ports equipped with valves (V2, V3, V4, and V5), and one
pressure gage. V2 controlled the aerosol flow from the OPL replica
cast to the chamber, V3 connected the chamber to a vacuum
pump, V4 opened the chamber to ambient air, and V5 controlled
aerosol flow from the chamber to the ESPARTA. V1 controlled
aerosol inhalation through the cast. The Aneroid pressure gauge
monitored the chamber’s vacuum pressure. The chambers inside
walls were lined with a grounded wire mesh. Figure 2 depicts the
experimental system. To characterize the DPI aerosols, Cheng
proposed that bolus inhalations be employed to promote realism
[30]. We adopted this methodology. Experiments started with
the evacuation of the aerosol sampling chamber to 35.6 cm of
mercury (0.5b) to simulate the inhalation of an aerosol bolus once
the inlet valves V1 and V2 were opened. The inhaled volume was
4 liters over 8 seconds at a flow rate of 30 L/min. The flow rate
was measured using an Extech Heavy Duty Hot Wire ThermoAnemometer (Extech Instruments, Waltham, Massachusetts,
J Drug Des Res 2(1): 1009 (2015)

Figure 2 Schematic of the experimental arrangement designed
to measure aerodynamic diameters and electrostatic charges
of DPI drug aerosol particles before and after passing through
the oral-pharyngeal-laryngeal (OPL) replica cast in real time.
Abbrevations: ESPARTA: Electronic Single Particle Relaxation Time
Analyzer.

USA). To characterize drug aerosols with or without passing
through the OPL replica cast, the DPI devices were actuated for
two experimental scenarios.

Scenario 1: At the inlet of the cast the instant before opening
V1, while V2 was open and V3, V4, and V5 were closed (i.e., inhaling
through the cast)
Scenario 2: At the inlet of the sampling chamber the instant
before V2 was open while V3, V4, and V5 were closed (i.e., bypassing the cast)

Prior to each run in the series of experiments, the aerosol
sampling chamber was vacuum cleaner and the cast was washed
with distilled water. To ensure that the inner walls of the sampling
chamber had the same effects on particle motion, the DPI devices
were actuated at the same inlet of the aerosol sampling chamber.
This supported an assumption of equal particle losses in the
scenarios described above. Once the sampling chamber was filled,
V1 was shut to implement Scenario 1, or V2 was shut to implement
Scenario 2, and V4 was opened for sampling by the ESPARTA
instrument for a period of 5 minutes for both scenarios 1 and 2. It
was unlikely; therefore, that a variation of drug quantity in each
dose from an individual inhaler affected the measurements and
comparisons of charged particles in each bolus. The procedure
was repeated for 5 consecutive runs. The sizes and charge
distributions were measured in each case. Raw data was acquired
through Lab View (National Instruments, Austin, Texas, USA) and
mined by Aerosol Particle Data Analyzer software (developed
at the Aerosol Drug Delivery Research Lab of the University of
Arkansas at Little Rock, Little Rock, Arkansas, USA).
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RESULTS AND DISCUSSION

350

In order to be able to compare the electromechanical
properties’ effects on the deposition fraction of the generated
aerosols from three DPIs, the particle aerodynamic size and
charge distributions are plotted in (Figures 3-5). Figure 3 shows
the comparison of the particle aerodynamic size distributions
of three DPIs. The 5-minute counts without passing through
the OPL cast were, Spiriva: 5923 ± 77, Advair: 5889 ± 20, and
Pulmicort: 5110 ± 25 (mean ± SD). Aerosols from the Spiriva and
Advair were widely distributed. The Pulmicort had a narrower
distribution than the other two. Figure 4 shows the comparisons
of the count median aerodynamic diameter (CMAD), and the
mass median aerodynamic diameter (MMAD) of three DPIs. The
CMAD and MMAD of Spiriva were 3.61 ± 0.07 µm, and 4.99 ± 0.03
µm, respectively; Advair were 3.61 ± 0.19 µm, and 5.29 ± 0.15
µm, respectively; and Pulmicort were 2.86 ± 0.02 µm, and 3.65
± 0.1 µm, respectively. Compared to the other two, Pulmicort
showed the best reproducibility result (geometric standard
deviation, GSD< 0.02). Figure 5 shows the electrostatic charge
distributions of three DPI aerosols. As can be seen, the Pulmicort
had less number of charged particles than the other two though
the share of negatively charged particles was higher for each DPI.
The inherent net charge to mass ratio was also negative for all of
them, e.g., Spiriva: -0.76 ± 0.11 µC/g, Advair: -0.49 ± 0.3 µC/g, and
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Figure 5 Particle electrostatic charge distributions of three different
DPI generated drug aerosols.

Pulmicort: -0.01 ± 0.02 µC/g. All three DPI aerosols contained both
positively and negatively charged particles. Spiriva and Advair
aerosol particles carried a large number of elementary charges.
As a result, deposition efficiency were greatly affected (Figure
6) by their charge distributions. The deposition fraction will be
defined as the ratio of the number of particles removed from
the aerosol (i.e., deposited) while traveling through the replica
OPL cast to the number of particles originally entering it. Table 1
shows the normalized data from 5 runs of charged particle counts
and both charged and uncharged particle deposition efficiencies
for each DPI. It also summarizes the count median aerodynamic
diameter (CMAD), mass median aerodynamic diameter (MMAD),
and electrostatic net charge to mass ratio (specific charge) for all
DPI aerosols before passing through the OPL replica cast.

Figure 3 Particle aerodynamic size distributions for three different
DPI generated drug aerosols.

As can be seen, oral-pharyngeal-laryngeal deposition of
all (charged and uncharged combined) particles of three DPIs
were, Spiriva: 22%, Advair: 61%, and Pulmicort: 7%. Comparing
the deposition patterns of charged and uncharged particles,
it was observed that the uncharged particles deposited much
less efficiently than the charged particles. Uncharged particle
depositions were, Spiriva: 34%, Advair: 51%, and Pulmicort:
8%, whereas, the charged particles depositions were, Spiriva:
68%, Advair: 67%, and Pulmicort: 28%. Some significant
differences in the deposition efficiencies between different
polarity particles were also observed. More negatively charged

Figure 4 Particle size analysis of three different DPI generated drug
aerosols (each bar represents mean ± SD).
Abbrevations: CMAD: count median aerodynamic diameter; MMAD:
mass median aerodynamic diameter

Figure 6 Comparison of the oral-pharyngeal-laryngeal deposition
fractions of the three dry powder inhaler aerosols.
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Table 1: Summary of the laboratory data.
Drug
Delivery
Device

Spiriva

TM

AdvairTM
PulmicortTM

5

1
DE OPL
All particles
Uncharged
Charged
22%
34%
68%
61%
51%
67%
7%
8%
28%

% of Charged
+ counts
- counts
62 %
1,783
1,899
67 %
1,626
2,313
28 %
475
618

Abbreviations:
1
DE OPL = Deposition efficiency in the Oral-Pharyngeal-Laryngeal Regions
2
Net q/m = Net charge/mass ratio
3
CMAD = count median aerodynamic diameter
4
MMAD = mass median aerodynamic diameter
5
All particles = both uncharged and charged particles

particles were deposited than were their positive counterparts.
For example, deposition of positive and negative particles of
Spiriva were 45% and 87%, respectively; Advair were 57%
and 74%, respectively; and Pulmicort were 0.2% and 54%,
respectively. Figure 6 represents the OPL cast deposition fraction
as a function of particle aerodynamic size, which shows how the
charged properties affected the deposition patterns. Although
the deposition fractions were increased linearly with increasing
particle size for all DPIs, the rate of increase was highest for the
one which contained the largest percentage of charged particles.
The generation of aerosols from a DPI depends upon 1) the
integration of inhaler design, 2) the drug and carrier powder
mixture formation, and 3) patient’s inspiratory effort. In this
study variable 1 and variable 2 are differed among the tested
DPIs. Therefore the difference in deposition observed in the
present study could be due to differences in design of inhaler
devices, flow properties, excipients, or active ingredients in
addition to electrostatic charge and particle size.

The study results of this work showed the Spiriva had the
highest number of charged (67%) particles, of which 41%
were positive and 59% were negative. The Adavair had the
second highest number of charged (62%) particles, of which
48% were positive and 52% were negative. Hence, there were
two electrostatic force situations. First of all, the uni-polar
charged particles induced greater space charge forces and
mutual repulsions. As a result, particles came closer to cast
walls and were captured. Secondly, bi-polar charged particles
agglomerated due to Coulombic attraction forces, which allowed
smaller particles to become larger and deposit more efficiently
within the cast due to inertial impaction. The agglomeration due
to electromagnetic forces is consistent with Finlay’s theory [20],
and the increased impaction (due to formations of larger sizes)
is consistent with the findings of Yu and Diu [31]. In contrast,
the Pulmicort had a relatively small amount (28%) of charged
particles, of which 43% were positive and 57% were negative.
As a result, very little agglomeration took place, and the aerosol
losses on cast walls were comparatively low (7%). During the
inhalation of an aerosol bolus, a complicated inlet velocity profile
J Drug Des Res 2(1): 1009 (2015)

Net q/m
+ ve q/m
- ve q/m
(µC/g)
- 0.76
+ 5.30
- 6.61
- 0.49
+ 4.77
- 6.30
- 0.46
+ 5.47
- 6.63

2

CMAD
(µm)
5
All particles
St. Dev.

MMAD
(µm)
5
All particles
St. Dev.

3.61
0.07

4.99
0.03

2.86
0.02

3.65
0.10

3

3.61
0.19

4

5.29
0.15

and flow conditions in the OPL replica cast may have affected
the abilities of particles to gain electrostatic charges through
tribo-electric charging processes [16,32]. Electrostatic charge
forces had major influences on the deposition properties of all
DPI aerosols. These influences were an indication of enhanced
charged particle deposition in the cast. Therefore, it can be
summarized that overall deposition efficiencies of charged
particles were higher than uncharged particles. This observation
agrees with Yu’s [22] mathematical model and the experimental
studies done by Hashish et al. [13] and Cohen et al. [14]. One study
reported that surface modification of carrier/excipient particle
can be reduced by using force control agents such as Plurionic
F-68, Cremophor RH40, soya lecithin, glyceryl monostearate, and
magnesium stearate [33]. Such attempts may reduce the gaining
of high charges of the aerosolized particles.
In this study, it is logical to recognize certain limitations. It
purposely avoided particles smaller than 0.5 µm because the
ESPARTA was not able to detect sizes below this limit; the OPL
replica cast was made of polyester resin; and it also assumed a
uniform state of temperature and humidity within the replica
cast; and no growth or evaporation of particles in transit. Within
this framework, this study did identify and quantitate the interrelated effects of electrostatic charges and particle sizes on the
deposition of various DPI aerosols. It is believed that the study
findings have practical values and clinical implications and
suggest that the developers of aerosol drug delivery devices
consider electrostatic charge effects while designing future
improved products.

CONCLUSION

In conclusion, this study demonstrates the electromechanical
properties (both aerodynamic size and electrostatic charge)
significant roles in the deposition of aerosols in the human oralpharyngeal-laryngeal regions. The DPI aerosol deposition in the
OPL region (often refers as extra thoracic region) is much less for
the drug delivery device that generates fewer charged aerosols
than for the others, a fact which clinicians may choose to consider
in inhalation therapy protocols.
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